nach oben

rheuma plus

Erschienen in:

01.06.2017 | JIA

Aktuelle Therapie der polyartikulären Verlaufsform der juvenilen idiopathischen Arthritis

verfasst von: Dr. A. Hospach, J. M. Rühlmann, F. Weller-Heinemann

Erschienen in: rheuma plus | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Polyarthritis ist mit ca. 20 % die dritthäufigste Verlaufsform der juvenilen idiopathischen Arthritis (JIA). Die Polyarthritis ist aber Ursache eines bedeutenden Teils der Krankheitslast und der Langzeitprobleme der JIA. Etablierte Therapieformen mit Steroiden und konventionellen „disease-modifying anti-rheumatic drugs“ (DMARDs) sind in den vergangenen Jahren insbesondere durch die Zulassung neuer Biologika erheblich erweitert worden. Die aktuellen Therapiemöglichkeiten werden hier dargestellt.

Vorheriger Artikel Kreuzschmerz – die meisten Pillen nützen wenig

Nächster Artikel Malignome und Infektionen unter Biologika

Petty RE et al (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392PubMed

Huppertz HI (2011) New criteria for the classification of rheumatoid arthritis: significance for child and adolescent rheumatology? Z Rheumatol 70(5):372–374CrossRefPubMed

Adib N et al (2008) Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study. Rheumatology (Oxford) 47(7):991–995CrossRef

Oen KG, Cheang M (1996) Epidemiology of chronic arthritis in childhood. Semin Arthritis Rheum 26(3):575–591CrossRefPubMed

Greenwald AG et al (2013) Later-onset rheumatoid factor negative polyarticular juvenile idiopathic arthritis (JIA): a unique patient group? Clin Exp Rheumatol 31(4):645–652PubMed

Saurenmann RK et al (2007) Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum 56(6):1974–1984CrossRefPubMed

Twilt M et al (2008) Long-term followup of temporomandibular joint involvement in juvenile idiopathic arthritis. Arthritis Rheum 59(4):546–552CrossRefPubMed

Hospach T et al (2014) Cervical spine involvement in patients with juvenile idiopathic arthritis – MRI follow-up study. Pediatr Rheumatol Online J 12:9CrossRefPubMedPubMedCentral

Elhai M et al (2013) Radiological cervical spine involvement in young adults with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 52(2):267–275CrossRef

10.

Ringold S et al (2009) Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford) 48(8):972–977CrossRef

11.

Ansell BM (1983) Juvenile chronic arthritis with persistently positive tests for rheumatoid factor (sero-positive juvenile rheumatoid arthritis). Ann Pediatr (Paris) 30(8):545–550

12.

Schanberg LE et al (2005) Pain, stiffness, and fatigue in juvenile polyarticular arthritis: contemporaneous stressful events and mood as predictors. Arthritis Rheum 52(4):1196–1204CrossRefPubMed

13.

Sabri K et al (2008) Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS 12(6):539–545CrossRefPubMed

14.

Kotaniemi K et al (2001) Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology 108(11):2071–2075CrossRefPubMed

15.

Heiligenhaus A et al (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 46(6):1015–1019CrossRef

16.

Angeles-Han ST et al (2013) Risk markers of juvenile idiopathic arthritis-associated uveitis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. J Rheumatol 40(12):2088–2096CrossRefPubMedPubMedCentral

17.

Heiligenhaus A et al (2013) Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm 21(3):180–191CrossRefPubMed

18.

Schmeling H et al (2014) Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol 66(9):2580–2589CrossRefPubMed

19.

Oen K et al (2003) Early predictors of longterm outcome in patients with juvenile rheumatoid arthritis: subset-specific correlations. J Rheumatol 30(3):585–593PubMed

20.

Minden K et al (2012) Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford) 51(8):1407–1415CrossRef

21.

Huppertz HI, Lehmann HW (2014) Evidence of treatment of chronic inflammation in childhood and adolescence with biologics. Z Rheumatol 73(10):907–916CrossRefPubMed

22.

Beukelman T, Brunner H et al (2016) Chapter 6. In: Petty R, Laxer R (Hrsg) Textbook of pediatric rheumatology. Elsevier, Philadelphia

23.

Guzman J et al (2015) The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 74(10):1854–1860CrossRefPubMed

24.

Dueckers G et al (2012) Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol 142(2):176–193CrossRefPubMed

25.

Beukelman T et al (2011) American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 63(4):465–482CrossRef

26.

Niehues T (2011) Leitlinien AWMF Register Nr. 027/020

27.

Hashkes PJ, Laxer RM (2005) Medical treatment of juvenile idiopathic arthritis. JAMA 294(13):1671–1684CrossRefPubMed

28.

Beukelman T et al (2012) Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol 39(9):1867–1874CrossRefPubMedPubMedCentral

29.

Giannini EH et al (1992) Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med 326(16):1043–1049CrossRefPubMed

30.

Alsufyani K et al (2004) The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 31(1):179–182PubMed

31.

Ruperto N et al (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50(7):2191–2201CrossRefPubMed

32.

Céspedes-Cruz A et al (2008) Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Ann Rheum Dis 67(3):309–314CrossRefPubMed

33.

Albers HM (2009) Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 61:46–51CrossRefPubMed

34.

Savolainen HA et al (1997) Azathioprine in patients with juvenile chronic arthritis: a longterm followup study. J Rheumatol 24(12):2444–2450PubMed

35.

Kvien TK, Hoyeraal HM, Sandstad B (1986) Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 13:118–123PubMed

36.

Curtis JR et al (2013) Clinical response within 12 weeks as a predictor of future low disease activity in early RA patients: results from the TEAR Trial. J Rheumatol 40(5):572–578CrossRefPubMedPubMedCentral

37.

Silverman E et al (2005) Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 352(16):1655–1666CrossRefPubMed

38.

Ringold S et al (2014) Childhood arthritis and rheumatology research alliance consensus treatment plans for new onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 66:1063–1072CrossRef

39.

Breit W et al (2000) A subgroup-specific evaluation of the efficacy of intraarticular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol 27(11):2696–2702PubMed

40.

Huppertz HI et al (2011) Progress in pediatric rheumatology: apprehend the opportunities of the future without forgetting the lessons from the past. Rheumatol Int 31(10):1259–1262CrossRefPubMedPubMedCentral

41.

Huppertz HI (2011) Recommendations for juvenile idiopathic arthritis by the American College of Rheumatology: comment on the article by Beukelman et al. Arthritis Care Res (Hoboken) 63(9):1354–1355 (author reply 1355–1356)CrossRef

42.

Lovell DJ et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342(11):763–769CrossRefPubMed

43.

Lovell DJ et al (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58(5):1496–1504CrossRefPubMed

44.

Papsdorf V, Horneff G (2011) Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford) 50(1):214–221CrossRef

45.

Nielsen S et al (2008) Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 26(4):688–692PubMed

46.

Horneff G et al (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 68(4):519–525CrossRefPubMed

47.

Beukelman T et al (2012) Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64:2773–2780CrossRefPubMedPubMedCentral

48.

Toussi SS et al (2013) Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis 57(9):1318–1330CrossRefPubMedPubMedCentral

49.

McCroskery P et al (2010) Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J 14(8):18–26CrossRef

50.

Beukelman T et al (2012) Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 64(4):1263–1271CrossRefPubMedPubMedCentral

51.

Simard JF et al (2010) Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum 62(12):3776–3782CrossRefPubMed

52.

Lovell DJ et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359(8):810–820CrossRefPubMed

53.

Brunner H, Ruperto N, Tzaribachev N et al (2014) A148: a multi-center, doubleblind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results. Arthritis Rheum 66:S191–S192CrossRef

54.

Ruperto N et al (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636):383–391CrossRefPubMed

55.

Brunner HI et al (2015) Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 74(6):1110–1117CrossRefPubMed

56.

Holzinger D et al (2012) The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 71(6):974–980CrossRefPubMed

57.

Swart JF, de Roock S, Wulffraat NM (2013) What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis? Arthritis Res Ther 15(3):213CrossRefPubMedPubMedCentral

Titel: Aktuelle Therapie der polyartikulären Verlaufsform der juvenilen idiopathischen Arthritis
verfasst von: Dr. A. Hospach
J. M. Rühlmann
F. Weller-Heinemann
Publikationsdatum: 01.06.2017
Verlag: Springer Vienna
Erschienen in: rheuma plus / Ausgabe 2/2017
Print ISSN: 1868-260X
Elektronische ISSN: 2191-2610
DOI: https://doi.org/10.1007/s12688-016-0090-2

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Rheuma und Sport

Interleukin-17 und seine Inhibitoren in der Therapie der Spondyloarthritiden

Der Placebo-Effekt korreliert mit der „Dramatik“ der Verabreichung

Grünlippmuschel-Extrakt bei Beschwerden des Stütz- und Bewegungsapparates

Kreuzschmerz – die meisten Pillen nützen wenig

Malignome und Infektionen unter Biologika